-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inhalants are a commonly used method of administration for patients with respiratory diseas.
Data shows that in recent years, the terminal inhalant market in public hospitals in key cities has grown steadily, with a growth rate of more than 10% in 2019, and double-digit growth in 2021, with sales exceeding 5 billion yu.
Since the beginning of this year, a number of inhalant varieties have been approved for marketi.
Recently, many pharmaceutical companies have continued to make efforts in the inhalation mark.
Four Trumpet Pharmaceuticals competes for the 7 billion inhalation large variety budesonide market, among which the 7 billion large inhalation variety budesonide, on May 24, Four Trumpreit Pharmaceuticals submitted 4 categories of budesonide nasal spray Generic listing applicati.
It is reported that the original pharmaceutical company of budesonide is AstraZeneca, and its best-selling products in China are budesonide nasal spray and budesonide suspension for inhalati.
The data shows that in 2021, budesonide will increase by 171% in China's urban public hospitals, China's county-level public hospitals, urban community centers and township health centers, returning to the level of 7 billion yu.
In the physical pharmacy terminals in Chinese cities, budesonide has maintained a positive growth trend in the past five years, and will exceed 400 million yuan in 202 In China's online pharmacy terminal, the growth rate of budesonide in 2020-2021 reached 767% and 149
Up to now, there are 6 types of inhalants that have been approved for marketing by Siprolite Pharmaceutica.
In addition to the budesonide nasal spray that has been declared for marketing this time, there are currently 10 types of inhalers in different clinical stag.
Warner Br.
makes efforts on levosalbutamol hydrochloride nebulized inhalation solution, which has surged by 3,20
On May 11, Hunan Warner Pharma submitted the listing application for levosalbutamol hydrochloride nebulized inhalation solution as generic drug categoryCDE undertakes acceptan.
Data shows that in 2021, the sales of levalbuterol hydrochloride atomized inhalation solution in public medical institutions in China will increase by more than 3,209% year-on-year, or about 200 million yu.
It is reported that levalbuterol is an adrenergic β-receptor agonist, which is the levorotatory body of salbutamol, and has the effect of relaxing bronchial smooth musc.
It can be clinically used for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseas.
Levosalbutamol inhalation solution was originally developed by Sepracor I.
of the United Stat.
The first inhalant of Kelun Pharmaceutical has entered the administrative approval stage, or will be approv.
According to the news on May 12, Hunan Kelun Pharmaceutical recently entered the administrative approval stage with the imitation of Class 4 ipratropium bromide solution for inhalati.
It is reported that in the field of inhalants, Kelun Pharmaceutical has 4 varieties submitted for marketing applications under the new registration classificati.
If the ipratropium bromide solution is successfully approved, it will become the first approved inhaler of Kelun Pharmaceutic.
Ipratropium bromide is a highly selective M receptor blocker with strong bronchial smooth muscle relaxation, suitable for maintenance treatment of bronchospasm caused by chronic obstructive pulmonary disease, including chronic bronchitis and pulmonary Emphysema,e.
Data show that in 2021, the sales volume of terminal ipratropium bromide inhalers in China's public medical institutions will increase by more than 319% year-on-year to nearly 1 billion yu.
Hengrui Medicine HRG2005 Inhaler Approved for ClinicalTrial HRG2005 can effectively control airway inflammation, reduce airway hyperresponsiveness, continuously dilate small airways, improve lung function and dyspnea, and at the same time can dilate bronchi and relieve airway trapping, so it can be used for chronic obstructive pulmonary disease (COPD) patients maintenance thera.
Up to now, Hengrui Medicine has invested about 245 million yuan in research and development on HRG2005 inhaler-related projec.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page wind.
_bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":""," bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina"," tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share To: ","viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","
Data shows that in recent years, the terminal inhalant market in public hospitals in key cities has grown steadily, with a growth rate of more than 10% in 2019, and double-digit growth in 2021, with sales exceeding 5 billion yu.
Since the beginning of this year, a number of inhalant varieties have been approved for marketi.
Recently, many pharmaceutical companies have continued to make efforts in the inhalation mark.
Four Trumpet Pharmaceuticals competes for the 7 billion inhalation large variety budesonide market, among which the 7 billion large inhalation variety budesonide, on May 24, Four Trumpreit Pharmaceuticals submitted 4 categories of budesonide nasal spray Generic listing applicati.
It is reported that the original pharmaceutical company of budesonide is AstraZeneca, and its best-selling products in China are budesonide nasal spray and budesonide suspension for inhalati.
The data shows that in 2021, budesonide will increase by 171% in China's urban public hospitals, China's county-level public hospitals, urban community centers and township health centers, returning to the level of 7 billion yu.
In the physical pharmacy terminals in Chinese cities, budesonide has maintained a positive growth trend in the past five years, and will exceed 400 million yuan in 202 In China's online pharmacy terminal, the growth rate of budesonide in 2020-2021 reached 767% and 149
Up to now, there are 6 types of inhalants that have been approved for marketing by Siprolite Pharmaceutica.
In addition to the budesonide nasal spray that has been declared for marketing this time, there are currently 10 types of inhalers in different clinical stag.
Warner Br.
makes efforts on levosalbutamol hydrochloride nebulized inhalation solution, which has surged by 3,20
On May 11, Hunan Warner Pharma submitted the listing application for levosalbutamol hydrochloride nebulized inhalation solution as generic drug categoryCDE undertakes acceptan.
Data shows that in 2021, the sales of levalbuterol hydrochloride atomized inhalation solution in public medical institutions in China will increase by more than 3,209% year-on-year, or about 200 million yu.
It is reported that levalbuterol is an adrenergic β-receptor agonist, which is the levorotatory body of salbutamol, and has the effect of relaxing bronchial smooth musc.
It can be clinically used for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseas.
Levosalbutamol inhalation solution was originally developed by Sepracor I.
of the United Stat.
The first inhalant of Kelun Pharmaceutical has entered the administrative approval stage, or will be approv.
According to the news on May 12, Hunan Kelun Pharmaceutical recently entered the administrative approval stage with the imitation of Class 4 ipratropium bromide solution for inhalati.
It is reported that in the field of inhalants, Kelun Pharmaceutical has 4 varieties submitted for marketing applications under the new registration classificati.
If the ipratropium bromide solution is successfully approved, it will become the first approved inhaler of Kelun Pharmaceutic.
Ipratropium bromide is a highly selective M receptor blocker with strong bronchial smooth muscle relaxation, suitable for maintenance treatment of bronchospasm caused by chronic obstructive pulmonary disease, including chronic bronchitis and pulmonary Emphysema,e.
Data show that in 2021, the sales volume of terminal ipratropium bromide inhalers in China's public medical institutions will increase by more than 319% year-on-year to nearly 1 billion yu.
Hengrui Medicine HRG2005 Inhaler Approved for ClinicalTrial HRG2005 can effectively control airway inflammation, reduce airway hyperresponsiveness, continuously dilate small airways, improve lung function and dyspnea, and at the same time can dilate bronchi and relieve airway trapping, so it can be used for chronic obstructive pulmonary disease (COPD) patients maintenance thera.
Up to now, Hengrui Medicine has invested about 245 million yuan in research and development on HRG2005 inhaler-related projec.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page wind.
_bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":""," bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina"," tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share To: ","viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","
